GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
70.55
-0.37 (-0.52%)
At close: 4:00PM EST

70.45 -0.10 (-0.14%)
After hours: 5:27PM EST

Stock chart is not supported by your current browser
Previous Close70.92
Open71.36
Bid70.13 x 800
Ask70.97 x 800
Day's Range70.17 - 71.71
52 Week Range64.27 - 89.54
Volume4,337,944
Avg. Volume6,675,556
Market Cap91.265B
Beta (3Y Monthly)1.39
PE Ratio (TTM)58.55
EPS (TTM)1.21
Earnings DateFeb 4, 2019 - Feb 8, 2019
Forward Dividend & Yield2.28 (3.17%)
Ex-Dividend Date2018-12-13
1y Target Est86.15
Trade prices are not sourced from all markets
  • Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels
    MarketWatch7 hours ago

    Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels

    Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.

  • Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges
    Zacks13 hours ago

    Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges

    With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.

  • Reuters2 days ago

    Express Scripts offers new formulary for lower list-price drugs

    Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled. The manager of prescription drug benefits for large corporate employers and government health plans said its new National Preferred Flex Formulary will be available as of Jan. 1 to all clients. Drug rebates have come under fire from the Trump Administration and consumer groups as patients find themselves paying much higher insurance co-payments and deductibles tied to a drug's sticker price.

  • Business Wire2 days ago

    Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27

    Webcast Available Through Gilead Corporate Website

  • Most Analysts Are Bullish on Nektar Stock
    Market Realist3 days ago

    Most Analysts Are Bullish on Nektar Stock

    In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.

  • Biotech stocks have been hit hard — here are ones analysts like best for a rebound
    MarketWatch4 days ago

    Biotech stocks have been hit hard — here are ones analysts like best for a rebound

    Nine companies have majority ‘buy’ ratings, with upside potential of as much as 123%, according to analysts.

  • Business Wire6 days ago

    Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018

    Gilead Sciences, Inc. (GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC). PSC is a rare, chronic condition that causes the network of ducts that drain bile from the liver to become inflamed and scarred over time. Progressive damage to the bile ducts in patients with PSC can lead to cirrhosis, liver failure, and cholangiocarcinoma (cancer of the bile ducts).

  • Business Wire6 days ago

    Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

    – Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need –

  • Business Wire6 days ago

    Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018

    Gilead Sciences, Inc. (GILD) today announced new data from the company’s clinical development program for advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Data presented support the ongoing development of the company’s investigational compounds, evaluate the utility of noninvasive tests for the identification of patients with advanced fibrosis, and demonstrate the significant burden of disease in affected patients. In this study, 140 NASH patients were treated with GS-9674 100 mg, GS-9674 30 mg or placebo orally once daily for 24 weeks.

  • Simply Wall St.6 days ago

    Is Gilead Sciences Inc’s (NASDAQ:GILD) Balance Sheet Strong Enough To Weather A Storm?

    Gilead Sciences Inc (NASDAQ:GILD), a large-cap worth US$91.0b, comes to mind for investors seeking a strong and reliable stock investment. Market participants who are conscious of risk tend to search Read More...

  • East Bay biotech scores $42 million with potential quick-fix for heart trouble
    American City Business Journals6 days ago

    East Bay biotech scores $42 million with potential quick-fix for heart trouble

    This company wants to make treating an irregular heartbeat as easy as reaching into your backpack, and it's just raised cash to take the first part of that vision into a mid-stage clinical trial.

  • Exclusive: Small Peninsula city urges developer to go bigger on new housing site
    American City Business Journals9 days ago

    Exclusive: Small Peninsula city urges developer to go bigger on new housing site

    After decades of anemic housing production, Belmont is luring more housing to its El Camino Real corridor including a new proposal for 250 apartments.

  • Why Gilead Sciences, Inc. Stock Broke Down in October
    Motley Fool9 days ago

    Why Gilead Sciences, Inc. Stock Broke Down in October

    Investors aren't pleased with Gilead's apparent lack of direction.

  • Gilead Sciences: Analysts’ Recommendations
    Market Realist10 days ago

    Gilead Sciences: Analysts’ Recommendations

    In November, among the 28 analysts covering Gilead Sciences (GILD), six recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold.” The mean rating for Gilead Sciences stock is 2.21 with a target price of $86.15, which implies an upside potential of 22.5% over Gilead Sciences’ closing price of $70.31 on November 1.

  • Analyzing Gilead Sciences’ HIV Portfolio
    Market Realist10 days ago

    Analyzing Gilead Sciences’ HIV Portfolio

    Gilead Sciences’ (GILD) total HIV sales got a boost from the US market. The HIV product sales in the United States increased from $2.52 billion in the third quarter of 2017 to $3.0 billion in the third quarter. The HIV product sales in Europe decreased from $656.0 million in the third quarter of 2017 to $584.0 million in the third quarter. The sales in other international markets decreased from $156.0 million in the third quarter of 2017 to $138.0 million in the third quarter. Gilead Sciences’ Biktarvy generated US sales of $375. ...

  • 3 Top Biotech Stocks With P/Es Below 14
    Motley Fool11 days ago

    3 Top Biotech Stocks With P/Es Below 14

    After a rough month, three top drugmakers are trading at bargain-basement prices.

  • Investopedia12 days ago

    Gilead Stock to Jump Double Digits: Morgan Stanley

    In a note to clients on Thursday, Morgan Stanley analysts downplayed the risk of an announcement by UnitedHealth Group Inc. ( UNH), which investors view as potentially eating into Gilead's revenues for its pricey drug treatments, as outlined by Barron's. Shares of Gilead plunged as much as 6% on Wednesday following news that UnitedHealth is launching a rewards program called My Scripts Reward, which promotes the use of low-cost therapies. Morgan Stanley analyst Matthew Harrison, who rates shares of the Foster City, Calif.-based biotechnology company at equal weight, noted a handful of issues with UnitedHealth's announcement.

  • TheStreet.com12 days ago

    Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

    GILD has been trying to turn itself around, but few, including Jim Cramer, see that turn coming any time soon. In this daily bar chart of GILD, below, has been struggling to mount a sustained rally. Is this the start of a new downtrend or just part of a longer base-building process?

  • Gilead Sciences’ Operational Performance
    Market Realist12 days ago

    Gilead Sciences’ Operational Performance

    Gilead Sciences’ (GILD) cost of goods sold increased marginally from $1.03 billion in the third quarter of 2017 to $1.09 billion in the third quarter.

  • What Does Gilead Sciences’ Bottom-Line Trend Indicate?
    Market Realist12 days ago

    What Does Gilead Sciences’ Bottom-Line Trend Indicate?

    Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter. The company’s income tax provision also decreased from $959.0 million in the third quarter of 2017 to $565.0 million in the third quarter.

  • Gilead Sciences: An Update for Investors
    Market Realist12 days ago

    Gilead Sciences: An Update for Investors

    For Gilead Sciences’ (GILD) Biktarvy, declining revenues and stock price movements have kept investors interested in the stock. In this series, we’ll explore Gilead Sciences’ financials, the performance of the company’s geographic segments, analysts’ recommendations for the stock, and the company’s valuation metrics.

  • bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat
    Zacks13 days ago

    bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat

    bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.

  • Decatur-based task force becoming ground zero for global elimination of hepatitis B and C
    American City Business Journals13 days ago

    Decatur-based task force becoming ground zero for global elimination of hepatitis B and C

    The Decatur-based Task Force for Global Health is becoming ground zero for the global elimination of hepatitis B and C.

  • Biotech ETFs in Focus on String of Q3 Earnings Beat
    Zacks13 days ago

    Biotech ETFs in Focus on String of Q3 Earnings Beat

    Biotech ETFs draw attention post impressive Q3 results.

  • Merck’s Virology Segment after the Third Quarter
    Market Realist14 days ago

    Merck’s Virology Segment after the Third Quarter

    Merck & Co.’s (MRK) Zepatier reported revenues of $104 million in the third quarter compared to $468 million in the third quarter of 2017, reflecting a ~78% YoY (year-over-year) decline and an 8% sequential decline.